Aspire Biopharma, Inc. (NASDAQ:PWUP)

BRIEF

published on 03/13/2025 at 13:35, 2 days 7 hours ago

Aspire Biopharma Updates on U.S. Patent Filings for Drug Delivery Platform

Clinical Trials Patent Applications Sublingual Delivery Rapid Absorption Aspirin Formulation
PRESS RELEASE

published on 03/13/2025 at 13:30, 2 days 7 hours ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Aspire Biopharma Holdings, Inc. provides update on patent applications for Oral Mucosal Formulations of Aspirin with rapid absorption technology. Company aims to revolutionize drug delivery and improve patient outcomes

Drug Delivery Technology Patent Applications Aspire Biopharma Oral Mucosal Formulations Aspirin
BRIEF

published on 03/03/2025 at 13:35, 12 days 7 hours ago

Aspire Biopharma Aims to Revolutionize Pre-Workout Supplements Market

Nutritional Supplements Fitness Industry Sublingual Technology Aspire Biopharma Pre-workout Market
PRESS RELEASE

published on 03/03/2025 at 13:30, 12 days 7 hours ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Aspire Biopharma announces plans to launch innovative single dose pre-workout supplement in 2025, leveraging sublingual delivery technology in a rapidly growing market

Nutritional Supplements Aspire Biopharma Pre-workout Supplement Sublingual Delivery Technology Fitness Products
BRIEF

published on 02/25/2025 at 13:35, 18 days 7 hours ago

Aspire Biopharma Updates Progress on High-Dose Sublingual Aspirin

FDA Approval Clinical Trials Pain Management Pharmaceutical Development Sublingual Aspirin
PRESS RELEASE

published on 02/25/2025 at 13:30, 18 days 7 hours ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Aspire Biopharma completes feasibility study on high-dose sublingual aspirin product, ready to start Phase 1 clinical trial in April 2025. Summary of expected 2025 milestones revealed

Feasibility Study Clinical Trial Milestones Aspire Biopharma Sublingual Aspirin
BRIEF

published on 02/21/2025 at 00:20, 22 days 20 hours ago

Aspire Biopharma Executes Securities Purchase Agreement

Convertible Debenture Securities Purchase Agreement Drug Development Capital Structure Aspire Biopharma
PRESS RELEASE

published on 02/21/2025 at 00:15, 22 days 20 hours ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
Aspire Biopharma, Inc. announces entering into a definitive Securities Purchase Agreement to issue a senior secured convertible debenture, strengthening capital structure and improving liquidity position

Convertible Debenture Securities Purchase Agreement Liquidity Position Capital Structure Aspire Biopharma Inc.
BRIEF

published on 02/20/2025 at 13:35, 23 days 7 hours ago

Aspire Biopharma Announces Nasdaq Listing Following Merger

FDA Approval Nasdaq Listing Business Combination Drug Delivery Innovation Aspire Biopharma
PRESS RELEASE

published on 02/20/2025 at 13:30, 23 days 7 hours ago

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
Aspire Biopharma completes business combination with PowerUp Acquisition Corp., forming Nasdaq-listed biopharmaceutical company focusing on FDA-approved drugs, nutraceuticals, and supplements

Biopharmaceutical Company Business Combination Aspire Biopharma Nasdaq-listed FDA-approved Drugs

Published on 03/15/2025 at 00:40, 20 hours 9 minutes ago

Star Copper Announces Execution of Arrangement Agreement For Spin-Out of Okeover Project
Published on 03/15/2025 at 00:00, 20 hours 49 minutes ago

BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement
Published on 03/14/2025 at 23:20, 21 hours 29 minutes ago

Organto Foods Provides Update on Strategic Plans
Published on 03/14/2025 at 22:55, 21 hours 54 minutes ago

Alset AI Announces Filing of Audited Financial Statements
Published on 03/14/2025 at 21:59, 22 hours 50 minutes ago

Apex Critical Metals Corp. Announces Grant of Stock Options

View all ACCESSWIRE

Published on 03/14/2025 at 20:20, 1 day ago

EQS-Adhoc: Gläubigerversammlung zur Anleihenverlängerung
Published on 03/14/2025 at 18:44, 1 day 2 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/14/2025 at 18:02, 1 day 2 hours ago

Form 8.1(c) - Dalata Hotel Group PLC:
Published on 03/14/2025 at 17:55, 1 day 2 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 03/14/2025 at 16:12, 1 day 4 hours ago

Thalassa Holdings Ltd: Trading Update

View all EQS

Published on 03/14/2025 at 18:55, 1 day 1 hour ago

Availability of ENGIE's 2024 Universal Registration Document
Published on 03/14/2025 at 18:00, 1 day 2 hours ago

Availability of the 2024 Universal Registration Document of OPmobility SE
Published on 03/14/2025 at 16:55, 1 day 3 hours ago

Closing of the agreement between ENGIE and the Belgian government
Published on 03/14/2025 at 11:34, 1 day 9 hours ago

Statement about the number of shares composing the share capital and the number of voting rights as at February 28, 2025
Published on 03/14/2025 at 08:44, 1 day 12 hours ago

Aéroports de Paris SA - €1bn dual-tranche new bond issue

View all LES ECHOS COMFI WIRE

News